NCT03496766 2025-03-05
Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS
Spanish Lung Cancer Group
Phase 2 Terminated
Clinical Trials
8 trialsNCT04865159 2023-09-21
Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies
Kura Oncology, Inc.
Phase 1 Terminated
NCT00847223 2018-08-23
Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma
Lymphoma Study Association
Phase 2 Terminated
NCT00360776 2017-04-05
Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00361088 2013-11-25
A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated
NCT00243035 2013-10-08
Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00124644 2013-05-03
Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00210028 2006-11-14
Study Assessing Efficacy of ZARNESTRAâ„¢ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer
Institut Claudius Regaud
Phase 2 Terminated